Anti-Toxoplasma gondii activities and structure-activity relationships of novel fluoroquinolones related to trovafloxacin

被引:18
作者
Khan, AA
Araujo, FG
Brighty, KE
Gootz, TD
Remington, JS
机构
[1] Palo Alto Med Fdn, Res Inst, Dept Immunol & Infect Dis, Palo Alto, CA 94301 USA
[2] Pfizer Inc, Div Cent Res, Groton, CT 06340 USA
[3] Stanford Univ, Sch Med, Dept Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA
关键词
D O I
10.1128/AAC.43.7.1783
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Eleven novel fluoroquinolones closely related to trovafloxacin were evaluated for their in vitro activity against Toxoplasma gondii, and their structure-activity relationships were examined, The 50% inhibitory concentration (IC50) of trovafloxacin against T. gondii was 2.93 mu M; the IC50 of the 11 analogs ranged from 0.53 to 14.09 mu M Six analogs had IC(50)s lower than that of trovafloxacin. Examination of the structure-activity relationships of the compounds revealed that addition of a -CH3 at C-5 of the 1,8-naphthyridone ring, at C-2 of the azabicyclohexane ring, or on the -NH2 at the 6 position of the azabicyclohexane ring resulted in a four- to sixfold increase in activity. Moreover, replacement of 2,4-difluorophenyl by cyclopropyl at N-1 of the 1,8-naphthyridone ring increased activity twofold, and moving the -NH2 one atom further away from the azabicyclohexane ring decreased activity. There was no difference between the naphthyridone and quinolone analogs. These results indicate that structure-activity studies of compounds related to drugs active against T. gondii may be useful in producing compounds with more potent activities against the parasite.
引用
收藏
页码:1783 / 1787
页数:5
相关论文
共 8 条
[1]   REMARKABLE INVITRO AND INVIVO ACTIVITIES OF THE HYDROXYNAPHTHOQUINONE 566C80 AGAINST TACHYZOITES AND TISSUE CYSTS OF TOXOPLASMA-GONDII [J].
ARAUJO, FG ;
HUSKINSON, J ;
REMINGTON, JS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1991, 35 (02) :293-299
[2]   DNA gyrase, topoisomerase IV, and the 4-quinolones [J].
Drlica, K ;
Zhao, XL .
MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS, 1997, 61 (03) :377-+
[3]   A plastid organelle as a drug target in apicomplexan parasites [J].
Fichera, ME ;
Roos, DS .
NATURE, 1997, 390 (6658) :407-409
[4]  
HOOPER DC, 1995, PRINCIPLES PRACTICE, V1, P364
[5]   Trovafloxacin is active against Toxoplasma gondii [J].
Khan, AA ;
Slifer, T ;
Araujo, FG ;
Remington, JS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (08) :1855-1859
[6]   Activity of trovafloxacin in combination with other drugs for treatment of acute murine toxoplasmosis [J].
Khan, AA ;
Slifer, T ;
Araujo, FG ;
Polzer, RJ ;
Remington, JS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (05) :893-897
[7]   Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones [J].
Pan, XS ;
Fisher, LM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (02) :471-474
[8]   PHARMACOKINETICS AND SAFETY OF TROVAFLOXACIN (CP-99,219), A NEW QUINOLONE ANTIBIOTIC, FOLLOWING ADMINISTRATION OF SINGLE ORAL DOSES TO HEALTHY MALE-VOLUNTEERS [J].
TENG, RL ;
HARRIS, SC ;
NIX, DE ;
SCHENTAG, JJ ;
FOULDS, G ;
LISTON, TE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1995, 36 (02) :385-394